Cover Image
QR Code

Management of Marginal Zone Lymphoma: A Canadian Perspective.

Marginal zone lymphomas (MZL) are a rare, heterogenous group of lymphomas, accounting for 5–17% of indolent non-Hodgkin lymphomas in the western world. They can be further divided into three subtypes: extranodal MZL, splenic MZL, and nodal MZL. These subtypes differ in clinical presentation and beha...

Full description

Published in:Current Oncology Vol. 30; no. 2; pp. 1745 - 1760
Main Authors: Peters, Anthea, Keating, Mary-Margaret, Nikonova, Anna, Doucette, Sarah, Prica, Anca
Format: Journal Article
Published: MDPI Feb2023
Online Access:View this record in EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=162118289&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 162118289
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        11980052
        5EKK
      jtl: Current Oncology
      issn: 11980052
      maglogo: N
    pubinfo:
      dt: Feb2023
      vid: 30
      iid: 2
      pid: 97109
      pub: MDPI
    artinfo:
      ui:
        162118289
        10.3390/curroncol30020135
        162118289
      ppf: 1745
      ppct: 15
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: Management of Marginal Zone Lymphoma: A Canadian Perspective.
      aug:
        au:
          Peters, Anthea
          Keating, Mary-Margaret
          Nikonova, Anna
          Doucette, Sarah
          Prica, Anca
        affil: Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB T6G 1Z2, Canada
      sug:
      ab: Marginal zone lymphomas (MZL) are a rare, heterogenous group of lymphomas, accounting for 5–17% of indolent non-Hodgkin lymphomas in the western world. They can be further divided into three subtypes: extranodal MZL, splenic MZL, and nodal MZL. These subtypes differ in clinical presentation and behavior, which influences how they are managed. There is currently no standard of care for the treatment of MZL, owing to the difficulty in conducting phase 3 randomized trials in MZL, and the fact that there are limited data on the efficacy of therapy in individual subtypes. Treatment practices are thus largely borrowed from other indolent lymphomas and are based on patient and disease characteristics, as well as access to therapy. This review summarizes the Canadian treatment landscape for MZL and how these therapies may be sequenced in practice.
      pubtype: Academic Journal
      doctype: Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N